CIPO Patents = 9

EPO Patents = 3

Forward Citations = 13

Loading Chart...

2 inventors (with patents filed for the assignee):

Thomas N Chase (7 out of 31 patents)

Kathleen E Clarence-Smith (7 out of 35 patents)

7 patents: Sort by Forward Citations

1. 11813248 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

2. 11813247 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

3. 11547700 - Compositions and methods for treating synucleinopathies (2023-01-10),

4. 11318122 - Pharmaceutical combination and its use for treating synucleinopathties (2022-05-03),

5. 11266633 - NK-1 antagonist compositions and methods for use in treating depression (2022-03-08),

6. 11160809 - NK1-antagonist combination and method for treating synucleinopathies (2021-11-02),

7. 10799484 - Compositions and methods for treating synucleinopathies (2020-10-13),

Company Overview

Chase Therapeutics Corporation is a biopharmaceutical company focused on developing novel therapies for the treatment of neurodegenerative diseases. Our mission is to improve the lives of patients by advancing innovative therapies that target the underlying mechanisms of neurodegeneration. With a team of experienced researchers and clinicians, we are dedicated to transforming the treatment landscape for neurodegenerative disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

7 Patents

#99 in Washington, DC

#99 in District of Columbia

#39,907 in US

Washington, DC, United States of America

Chase Therapeutics Corporation

Forward Citations = 13

2 inventors:

Thomas N Chase (7 out of 31 patents)

Kathleen E Clarence-Smith (7 out of 35 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chase Therapeutics Corporation. Retrieved from https://idiyas.com/company/chase-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

9 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]